Vertex Pharmaceuticals INC / Ma (VRTX) — SEC Filings

Overview

Vertex Pharmaceuticals INC / Ma (VRTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Vertex Pharmaceuticals Inc. reported a significant increase in net income and product revenues for the three and nine months ended September 30, 2025. Product revenues, net, rose to $3,076.4 million for the three months ended September 30, 2025, up from $2,771.9 million in the same period of 2024, r

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 3 bullish, 29 neutral. The dominant filing sentiment for Vertex Pharmaceuticals INC / Ma is neutral.

Filing Type Overview

Vertex Pharmaceuticals INC / Ma (VRTX) has filed 6 10-Q, 17 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (32)

• Vertex Soars on Strong Revenue Growth, Swings to Profit — 10-Q · Nov 4, 2025 Risk: medium
  Vertex Pharmaceuticals Inc. reported a significant increase in net income and product revenues for the three and nine months ended September 30, 2025. Product r
• 8-K Filing — 8-K · Nov 3, 2025
• Vertex Pharma's Q2 Revenue Jumps 16.7% on Strong Product Sales — 10-Q · Aug 5, 2025 Risk: medium
  VERTEX PHARMACEUTICALS INC / MA reported robust financial performance for the second quarter ended June 30, 2025, with total revenue reaching $2.73 billion, a s
• Vertex Pharmaceuticals Files 8-K on Financials and Personnel — 8-K · Aug 4, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on August 4, 2025, reporting on results of operations, financial condition, and changes in its board and office
• Vertex Pharmaceuticals Files 8-K — 8-K · May 19, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 19, 2025, reporting "Other Events." The filing does not contain specific details about the nature of the
• Vertex Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · May 14, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 14, 2025, to report on matters submitted to a vote of its security holders. The filing details the compa
• Vertex Pharma Q1 2025 Filing: Financial Snapshot — 10-Q · May 6, 2025 Risk: low
  Vertex Pharmaceuticals Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing details its financial position, i
• Vertex Pharmaceuticals Files 8-K on Financials — 8-K · May 5, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 5, 2025, to report on its results of operations and financial condition, as well as to file financial st
• Vertex Pharma DEF 14A: Executive Compensation Details — DEF 14A · Apr 3, 2025 Risk: low
  Vertex Pharmaceuticals Inc. filed its DEF 14A on April 3, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, includi
• Vertex Pharmaceuticals Files 8-K — 8-K · Mar 28, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on March 28, 2025, to report other events. The filing does not contain specific details about the nature of the
• Vertex Pharmaceuticals Files 2024 10-K — 10-K · Feb 13, 2025 Risk: low
  Vertex Pharmaceuticals Inc. filed its 2024 10-K on February 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Bosto
• Vertex Pharmaceuticals Director Departs; Financials Filed — 8-K · Feb 10, 2025 Risk: low
  Vertex Pharmaceuticals Incorporated announced on February 4, 2025, the departure of Dr. Paul J. W. Stone, a member of its Board of Directors. The company also r
• Vertex Pharmaceuticals Files 8-K Disclosure — 8-K · Dec 20, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on December 20, 2024, to report information under Regulation FD. The filing does not contain specific details a
• Vertex Pharmaceuticals Q3 2024 Update — 10-Q · Nov 5, 2024 Risk: low
  Vertex Pharmaceuticals Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements indicate ongoing ope
• Vertex Pharmaceuticals Files 8-K on Financials — 8-K · Nov 4, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition, as well as financial state
• Vertex Pharmaceuticals Enters Material Definitive Agreement — 8-K · Aug 16, 2024 Risk: medium
  On August 15, 2024, Vertex Pharmaceuticals Incorporated entered into a material definitive agreement. The filing does not disclose the specific details of this
• Vertex Pharmaceuticals Q2 2024 Update — 10-Q · Aug 2, 2024 Risk: low
  Vertex Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2024. The company's filing details its financial position and performa
• Vertex Pharmaceuticals Files 8-K on Financials — 8-K · Aug 1, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition, as well as financial stateme
• Vertex Pharmaceuticals Files Routine 8-K — 8-K · Jun 27, 2024 Risk: low
  On June 27, 2024, Vertex Pharmaceuticals Incorporated filed an 8-K report. The filing indicates no specific material events or transactions requiring immediate
• Vertex Pharmaceuticals Files 8-K — 8-K · May 20, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 20, 2024, to report other events and financial statements. The filing details the company's principal ex
• Vertex Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · May 15, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 15, 2024, to report on the submission of matters to a vote of security holders. The filing indicates tha
• Vertex Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Vertex Pharmaceuticals reported financial results for the qu
• Vertex Pharmaceuticals Files 8-K on Financials — 8-K · May 6, 2024 Risk: low
  Vertex Pharmaceuticals Incorporated filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing includes financial s
• Vertex Pharmaceuticals Enters Material Definitive Agreement — 8-K · Apr 11, 2024 Risk: medium
  On April 10, 2024, Vertex Pharmaceuticals Incorporated entered into a Material Definitive Agreement. The filing also includes information on Other Events and Fi
• SC 13G/A Filing — SC 13G/A · Apr 10, 2024
• Vertex Pharmaceuticals Inc. files DEF 14A with executive compensation details — DEF 14A · Apr 4, 2024 Risk: low
  VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Vertex Pharmaceuticals Inc. filed a DEF 14A on April 4,
• Vertex Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk: medium
  VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Annual Report (10-K) with the SEC on February 15, 2024. Vertex Pharmaceuticals Inc. filed its 2023 Form 10-K on F
• Vanguard Amends Vertex Pharma Stake: No Voting Power Reported — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, indicating its beneficial ownership of Vertex Pharmaceuticals Inc.
• Capital World Investors Holds 22M Shares of Vertex Pharma — SC 13G/A · Feb 9, 2024 Risk: low
  Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing its ownership in Vertex Pharmaceuticals Inc.
• FMR LLC & Abigail Johnson Maintain 5.037% Stake in Vertex Pharma — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Vertex Pharmaceuticals Inc. As of December
• Vertex Pharma Files 8-K on Financial Results, Operations — 8-K · Feb 5, 2024
  Vertex Pharmaceuticals Incorporated filed an 8-K on February 5, 2024, to announce its results of operations and financial condition. This filing indicates that
• BlackRock Discloses Passive Stake in Vertex Pharmaceuticals — SC 13G · Jan 25, 2024
  BlackRock Inc., a major investment firm, has filed an SC 13G indicating its ownership of shares in Vertex Pharmaceuticals Inc. / MA as of December 31, 2023. Thi

Related Companies

CRSP

Frequently Asked Questions